News & Events
KaloBios Raises Additional $12 Million in Series D Venture Financing for a New Total of $32 Million
12 / 12 / 2008
ChemGenex's Omacetaxine Demonstrates 80% Complete Hematological Response Rate in Drug-Resistant CML Patients with the T315I Mutation
09 / 12 / 2008
Hatchtech $2.5m new funding for Phase II head lice trials. Hatchtech to attain proof of clinical concept in affected patients
08 / 12 / 2008
Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes
23 / 10 / 2008
ChemGenex Completes $A12.9 Million Capital Raising Announces Share Purchase Plan for existing Australian resident shareholders
17 / 09 / 2008
Displaying records 501-525 of 705